OGN

Organon & Co

Add to Watchlist

Advanced Chart

9.970

-0.24(-2.351%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

10.180

Open

10.170

VWAP

Vol

2.90M

Mkt Cap

2.59B

Low

9.935

Amount

EV/EBITDA(TTM)

6.61

Total Shares

257.17M

11.06B

EV/OCF(TTM)

11.79

P/S(TTM)

0.42

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

1.60B

+0.4%

0.941

+4.51%

1.55B

-1.82%

0.940

+8%

1.56B

-3.06%

0.940

-16.05%

Estimates Revision

The market is revising Downward the revenue expectations for Organon & Co. (OGN) for FY2025, with the revenue forecasts being adjusted by -1.18% over the past three months. During the same period, the stock price has changed by -24.24%.

Revenue Estimates for FY2025

Revise Downward

-1.18%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.92%

In Past 3 Month

Stock Price

Go Down

-24.24%

In Past 3 Month

7 Analyst Rating

40.42% Upside

Wall Street analysts forecast OGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGN is 14.00 USD with a low forecast of 10.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

2 Sell

Hold

40.42% Upside

Current: 9.970

Low

10.00

Averages

14.00

High

18.00

40.42% Upside

Current: 9.970

Low

10.00

Averages

14.00

High

18.00

Piper Sandler

David Amsellem

Overweight

downgrade

$24 -> $18

2025-05-15

Reason

Piper Sandler

David Amsellem

Price Target

$24 -> $18

2025-05-15

downgrade

Overweight

Reason

Morgan Stanley

Terence Flynn

Hold

Maintains

$16 → $15

2025-04-09

Reason

Morgan Stanley

Terence Flynn

Price Target

$16 → $15

2025-04-09

Maintains

Hold

Reason

Morgan Stanley lowered the firm's price target on Organon to $15 from $16 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.

Morgan Stanley

Terence Flynn

Hold

Maintains

$17 → $16

2025-02-14

Reason

Morgan Stanley

Terence Flynn

Price Target

$17 → $16

2025-02-14

Maintains

Hold

Reason

Barclays

Balaji Prasad

Buy

Maintains

$26 → $24

2025-02-14

Reason

Barclays

Balaji Prasad

Price Target

$26 → $24

2025-02-14

Maintains

Buy

Reason

Barclays analyst Balaji Prasad lowered the firm's price target on Organon to $24 from $26 and keeps an Overweight rating on the shares. The shares rallied post the Q4 report, owing to reaffirmation of steady fundamentals, the analyst tells investors in a research note.

JP Morgan

Chris Schott

Hold

Sell

Downgrades

$18 → $20

2024-09-06

Reason

JP Morgan

Chris Schott

Price Target

$18 → $20

2024-09-06

Downgrades

Hold

Sell

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Organon & Co (OGN.N) is 2.65, compared to its 5-year average forward P/E of 5.03. For a more detailed relative valuation and DCF analysis to assess Organon & Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

5.03

Current PE

2.65

Overvalued PE

6.33

Undervalued PE

3.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

6.72

Current EV/EBITDA

5.61

Overvalued EV/EBITDA

7.83

Undervalued EV/EBITDA

5.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

0.95

Current PS

0.43

Overvalued PS

1.28

Undervalued PS

0.63

Financials

Annual

Quarterly

FY2025Q1

YoY :

-6.72%

1.51B

Total Revenue

FY2025Q1

YoY :

-21.17%

324.00M

Operating Profit

FY2025Q1

YoY :

-56.72%

87.00M

Net Income after Tax

FY2025Q1

YoY :

-57.69%

0.33

EPS - Diluted

FY2025Q1

YoY :

+10.00%

-22.00M

Free Cash Flow

FY2025Q1

YoY :

-5.80%

55.58

Gross Profit Margin - %

FY2025Q1

YoY :

+28.95%

9.31

FCF Margin - %

FY2025Q1

YoY :

-53.59%

5.75

Net Margin - %

FY2025Q1

YoY :

-35.85%

14.26

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

551.0K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

172.4K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

8.4K

Volume

Months

6-9

9.9K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

551.0K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

OGN News & Events

Events Timeline

2025-07-07 (ET)

2025-07-07

07:38:11

Organon announces American Academy of Dermatology recommendation for Vtama cream

2025-07-02 (ET)

2025-07-02

07:35:51

Organon ELENA trial misses primary endpoint, to discontinue OG-6219 program

2025-05-27 (ET)

2025-05-27

07:35:45

Organon announces FDA designates Hadlima as biosimilar to Humir

News

7.0

07-22Globenewswire

Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses. July 22, 2025 Deadline to file Lead Plaintiff Motion

7.0

07-22Globenewswire

DEADLINE ALERT for OGN, RCAT, FTRE, VSTS: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

7.0

07-22Globenewswire

ORGANON FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit